瑞博西尼联合内分泌治疗早期乳腺癌 - Suppr | 超能文献

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

作者信息

Tannock Ian F, Meirson Tomer, Fojo Antonio

机构信息

Princess Margaret Cancer Centre, Toronto, ON, Canada

Davidoff Cancer Center, Petah Tikva, Israel.

出版信息

N Engl J Med. 2024 Jun 20;390(23):2220-2221. doi: 10.1056/NEJMc2404917.

DOI:10.1056/NEJMc2404917

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Ribociclib plus Endocrine Therapy in Early Breast Cancer.瑞博西尼联合内分泌治疗早期乳腺癌

N Engl J Med. 2024 Jun 20;390(23):2220-2221. doi: 10.1056/NEJMc2404917.

2

Ribociclib plus Endocrine Therapy in Early Breast Cancer.瑞博西尼联合内分泌治疗早期乳腺癌

N Engl J Med. 2024 Jun 20;390(23):2219-2220. doi: 10.1056/NEJMc2404917.

3

Ribociclib plus Endocrine Therapy in Early Breast Cancer.瑞博西尼联合内分泌治疗早期乳腺癌

N Engl J Med. 2024 Jun 20;390(23):2220. doi: 10.1056/NEJMc2404917.

4

Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.瑞博西尼联合内分泌治疗早期乳腺癌。回复。

N Engl J Med. 2024 Jun 20;390(23):2221-2222. doi: 10.1056/NEJMc2404917.

5

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.瑞博西尼，一种细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂，联合内分泌治疗用于亚洲晚期乳腺癌女性患者。

Cancer Sci. 2020 Sep;111(9):3313-3326. doi: 10.1111/cas.14554. Epub 2020 Jul 28.

6

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.来曲唑联合内分泌治疗与安慰剂联合内分泌治疗用于激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的成本效果分析。

J Manag Care Spec Pharm. 2021 Mar;27(3):327-338. doi: 10.18553/jmcp.2021.27.3.327.

7

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.CDK4/6 抑制剂联合内分泌治疗与单独内分泌治疗用于高危浸润性 HR+/HER2-早期乳腺癌辅助治疗的疗效和安全性：随机临床试验的综合更新荟萃分析。

Breast. 2024 Dec;78:103815. doi: 10.1016/j.breast.2024.103815. Epub 2024 Oct 15.

8

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.种族对晚期乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂疗效和毒性的影响：荟萃分析。

Breast Cancer Res Treat. 2019 Feb;174(1):271-278. doi: 10.1007/s10549-018-5054-x. Epub 2018 Nov 21.

9

Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.来曲唑与阿那曲唑治疗绝经后激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的疗效和安全性的 Meta 分析

Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213. doi: 10.1080/14737140.2018.1435275. Epub 2018 Feb 19.

10

Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.符合辅助性CDK4/6抑制剂治疗条件的乳腺癌患者的真实世界分析。

Clin Breast Cancer. 2025 Feb;25(2):e159-e169.e2. doi: 10.1016/j.clbc.2024.08.022. Epub 2024 Aug 29.

引用本文的文献

1

Reassessing estrogen receptor expression thresholds for breast cancer prognosis in HER2-negative patients using shape restricted modeling.使用形状受限模型重新评估HER2阴性患者乳腺癌预后的雌激素受体表达阈值。

Sci Rep. 2025 Feb 15;15(1):5590. doi: 10.1038/s41598-025-90134-9.